All doses of Eli Lilly’s weight-loss drugs Zepbound and Mounjaro are available in the U.S. after more than a year of shortages, according to the Food and Drug Administration’s (FDA) drug shortage database.
As of Friday, at least four strengths of Mounjaro and Zepbound had been listed on the FDA website as out of stock in the US.
The agency still lists a general shortage of the drugs, meaning potentially dangerous compounded versions of this drug are still allowed on the market.
Compounding pharmacies can manufacture a drug that is essentially a copy of a commercially available drug if its active ingredients are listed on the FDA’s drug shortage list.
Lilly has been warning patients about sales and social media posts involving fake or compounded versions of tirzepatide, the active ingredient in Zepbound and Mounjaro,
Mounjaro is a diabetes medication and the FDA approved Zepbound for weight loss last year. Its main competitor, Wegovy, is still missing.
This story originally appeared on thehill.com read the full story
